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Abstract
HerGa is a self-assembled tumor-targeted particle that bears both tumor detection and elimination
activities in a single, two-component complex (Agadjanian et al., 2009, PNAS 106:6105–6110).
Given its multifunctionality, HerGa (comprised of the fluorescent cytotoxic corrole macrocycle,
S2Ga, noncovalently bound to the tumor-targeted cell penetration protein, HerPBK10) has the
potential for high clinical impact, but its mechanism of cell killing remains to be elucidated, and
hence is the focus of the present study. Here we show that HerGa requires HerPBK10-mediated
cell entry to induce toxicity. HerGa (but not HerPBK10 or S2Ga alone) induced mitochondria
membrane potential disruption and superoxide elevation, which were both prevented by
endosomolytic-deficient mutants, indicating that cytosolic exposure is necessary for corrole-
mediated cell death. A novel property discovered here is that corrole fluorescence lifetime acts as
a pH indicator, broadcasting the intracellular microenvironmental pH during uptake in live cells.
This feature in combination with two-photon imaging shows that HerGa undergoes early
endosome escape during uptake, avoiding compartments of pH<6.5. Cytoskeletal disruption
accompanied HerGa-mediated mitochondrial changes whereas oxygen scavenging reduced both
events. Taxol-treatment indicated that HerGa uptake requires dynamic microtubules.
Unexpectedly, low pH is insufficient to induce release of the corrole from HerPBK10. Altogether,
these studies identify a mechanistic pathway in which early endosomal escape enables HerGa-
induced superoxide generation leading to cytoskeletal and mitochondrial damage, thus triggering
downstream cell death.
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INTRODUCTION
Whereas cancer treatment by porphyrins and related macrocyclic compounds has been
investigated extensively for many decades 1, 2, the therapeutic potential of corroles has only
recently been disclosed 3, 4. Sulfonated corroles are water soluble (amphipolar) macrocyclic
compounds, whose Fe(III) and Mn(III) complexes are very active catalysts for
decomposition of reactive oxygen and nitrogen species involved in a variety of relevant
diseases. 5–9 Also noteworthy is the finding that Ga(III) and Al(III) derivatives are intensely
fluorescent at relatively long wavelengths 10, 11. While these metal complexes are capable of
undergoing endocytosis via co-uptake with, or noncovalent attachment to, serum proteins in
vitro and in vivo, they are unable to penetrate cell membranes without facilitation by
membrane-lytic molecules. Hence, toxic corroles, such as the Ga(III) derivative, are safe at
pharmacologic doses but can kill cells when allowed to breach into the cytosol 12.
Our investigations of S2Ga, the Ga(III) –metallated derivative of the sulfonated corrole,
have shown that it noncovalently attaches to the ligand-directed cell penetration protein
HerPBK10 with sufficient stability as to not exchange with serum proteins 3, 12. We have
further shown that HerGa (resulting from the noncovalent assembly of S2Ga and
HerPBK10) can selectively target and kill HER2+ tumor cells in a mixed culture of HER2+
and HER2− cells 3 at submicromolar concentrations while the individual components
comprising HerGa do not elicit cell death 3, 12.
Cell targeting by HerPBK10 is directed by the incorporation of the receptor-binding domain
of heregulin, which has enhanced affinity for the human epidermal growth factor receptor
(HER) heterodimer (HER2/3 or HER2/4) when the HER-2 subunit is amplified, such as in
HER2+ tumors 13, 14. These tumors comprise the most aggressive and recalcitrant cancers
with the worst prognosis among breast, prostate, and glioma tumors 15–19, thus patients
could benefit from targeted interventions. Current targeted therapies aimed at blocking
proliferative signaling are ineffective in up to 70% of cases likely due to signaling mutations
accumulated in tumor cells 20, 21, hence alternative targeting strategies that circumvent
signal inhibition (such as the direct delivery of toxic molecules into tumor cells) could
provide needed improvements. Accordingly, HerPBK10 was designed to enter cells via
HER binding and rapid ligation-triggered internalization, followed by endosomal
penetration via the adenovirus-derived penton base domain engineered into the
protein 3, 12, 22. Importantly, the current monoclonal antibodies used clinically for targeted
therapy of HER2+ tumors do not undergo receptor-mediated endocytosis or membrane
penetration.
Our previous studies have shown that HerGa binds tumor cells through competitively-
inhibitable HER binding, and undergoes endocytosis after receptor binding 12. We have also
shown that the corrole (detected by virtue of its fluorescence) remains sequestered
throughout the cytoplasm and excluded from the nucleus 3, 12, thus pointing to cytosolic
rather than nuclear factors as the targets of corrole-mediated cytotoxicity in human breast
cancer cells 12. The relevance of these studies to in vivo systems was demonstrated in tumor-
implanted mice, which showed that HerPBK10 enables corrole targeting and uptake into
HER2+ tumors that can be readily visualized due to the intense corrole fluorescence, and
this tumor targeting resulted in tumor growth inhibition at >5-times lower dosage in
comparison to systemic delivery of the chemotherapy agent, doxorubicin 3, 4. These initial
successes in testing corroles for tumor-targeted therapy have highlighted the need to
elucidate the underlying mechanisms that contribute to corrole-mediated cytotoxicity.
The focus of this study is to examine the intracellular changes taking place after HerGa
uptake that precede cell death, so as to delineate the events that cause HerGa-mediated
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toxicity. The present study shows that HerGa, but not HerPBK10 or S2Ga alone,
compromises mitochondrial membrane potential [ΔΨ(m)] and disrupts the cytoskeleton
through superoxide elevation, for which escape from endosomal vesicles after cell uptake is
key. While low pH does not induce corrole release from the carrier, HerGa avoids highly
acidic intracellular compartments, as assessed by fluorescence lifetime imaging, two-photon
imaging and through the use of endosomolytic-defective versions of the carrier protein.
Importantly, the fluorescence lifetime characteristics of the corrole enabled us to identify the
intracellular compartmental pH of its surrounding microenvironment during cellular uptake,
thus acting as a pH indicator in live cells. Studies with taxol indicate that dynamic
microtubules are required for HerGa uptake. These findings have allowed us to identify for
the first time the intracellular events that facilitate HerGa interaction with target cells
leading to corrole-mediated cytotoxicity, and may be applicable to a broad range of tumors
depending on the delivery vehicle.
MATERIALS AND METHODS
Materials
HerPBK10, HerK10, and Her protein and was produced in and isolated from a bacterial
protein expression system as described previously 23. Gallium-metallated sulfonated corrole
was synthesized, reconstituted in phosphate-buffered saline (PBS), and quantified as
described previously 12. HerGa, HerGa-2 and HerGa-3 complexes were assembled by
combining each protein and S2Ga at corrole:protein ratios of 30, 5, or 8, respectively, and
incubating mixtures with gentle agitation on ice for 1h, followed by ultrafiltration through a
50 kDa MWCO Filter Column (Millipore, Billerica, MA, USA) that has been coated with
10% glycerol. The column was spun at 1000×G until the filtrate clarified and the volume
was reduced to <500uL. Concentrations used for cell treatments are based on the corrole
concentration in each complex, determined by obtaining the λmax absorption using UV/Vis
spectroscopy and applying the equation: (absorbance at λmax/corrole extinction coefficient)
× dilution factor = concentration (M).
Cells
MDA-MB-435 cells were obtained from the National Cancer Institute and maintained at
37°C in DMEM, 10% fetal bovine serum at 5% CO2. All cell treatments were performed at
~36h after plating to allow sufficient receptor re-expression and display on the cell surface.
Live cell microscopy of internalized reagents
At ~36h after MDA-MB-435 cells were plated in delta T chambers (105/well), the media
was replaced with HBSS containing 1 uM HerGa or S2Ga, followed immediately by
acquisition of confocal images every 5 minutes. To image HerGa internalization −/+ taxol,
confocal images were acquired at different depths (~10 micron sections at 1 micron steps)
every 5 min for 1h. Excitation and emission wavelengths at 560nm and 620nm+/−20nm,
respectively, were selected for HerGa detection.
Cell death dose curve
Cells were plated at 104 cells per well in a 96 well dish. 36 hours later the media was
aspirated and replaced with 50uL complete DMEM containing the indicated concentrations
of HerGa. The cells were rocked at 37°C for four hours, after which an additional 50uL of
complete media was added and cells continued incubation at 37°C without rocking. 24 hours
after the start of the treatment the cell number was determined by the crystal violet (CV)
assay. Briefly, the media was aspirated and cells were washed with PBS containing 0.01%
Mg++ and 0.01% Ca++. The PBS was aspirated and each well was stained with 0.1% Crystal
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Violet at RT for 15 min. The cells were then washed in PBS with Mg++/Ca++ 4 times. After
the final wash, each well received 100uL 95% ethanol to release the CV. The plate was
incubated at RT for 10 minutes before the absorbance at 590nm was measured.
Mitochondrial membrane potential measurement
The distribution of the cationic dye, tetramethyl rhodamine methyl ester (TMRM), across
the mitochondria membrane is governed primarily by the Nernst equation 24, whereas
transmembrane potential collapse results in its diffusion into the cytosol and thus reducing
its intracellular fluorescence intensity 25. MDA-MB-435 cells were plated in Delta T
chambers at 104 cells/chamber, and incubated for 36 hours, after which media was aspirated
from each chamber and replaced with 0.5 mL fresh complete media containing HerGa,
S2Ga, HerPBK10, or PBS at the indicated concentrations. Each chamber was rocked for 4h
at 37° C, 5% CO2, then received 0.5 mL additional media bringing the final volume to 1mL,
after which chambers were incubated another 20 hours. The media was then aspirated and
replaced with 20nM TMRM in PBS, and two-photon excited confocal TMRM fluorescence
images were acquired at different z-depths after TMRM accumulation reached equilibrium
(~1 hour). Mitochondrial membrane potential was quantified from a z-stacked maximum
intensity projection of each acquired image by calculating the fluorescence intensity ratio of
mitochondrial to cytoplasm sites (10, 11). In calculating the mitochondria/cytoplasm ratio,
average fluorescence intensity for 10 different mitochondria regions and one mitochondria-
free region (distinguishing the cytoplasm) within the same cells were measured respectively.
This calculation was performed for all cells in each field of view from three independent
experiments.
Fluorescence lifetime detection
Fluorescence lifetime imaging was performed using a femtosecond (fs) pulsed laser (Mai
Tai, Spectra Physics) light tuned to 424nm, at a repetition rate of 80Mhz, generated by the
second harmonic of a fs pulsed laser at 848nm in a Beta Barium Borate (BBO) crystal,
delivered to a Nikon Microscope through macro lenses, a diffuser, a band-pass filter
(425±5nm), and several mirrors. The delivered light was reflected to the back focal plane of
a 100x objective (Nikon 100x planfluor, NA: 1.3) for the excitation of the HerGa.
Fluorescence emission from HerGa was collected by the objective and delivered onto a CCD
connected with time-gated intensifier (TGI) (Lavison) through an emission filter
(620±60nm), and then fluorescence lifetime images of HerGa acquired at indicated points.
Superoxide detection
MDA-MB-435 grown in 96 well plates at 1×104/well for 36 hours were aspirated of medium
and received fresh medium containing HerGa or S2Ga (at 1 uM corrole concentration),
HerPBK10 (at equivalent protein concentration to HerGa), or PBS (mock), followed by
incubation for 1h at 37°C. The cells were then assayed for superoxide generation by
measuring luminol oxidation following a commercial procedure (LumiMax Superoxide
Anion detection kit; Agilent Technologies, Santa Clara, CA, USA). Light emission was
recorded every 1 min for 30 min by a Veritas Microplate Luminometer (Promega
Corporation, Sunnyvale, CA, USA). Where indicated, cells were pre-incubated in Tiron at
the indicated concentrations for 1h before treatment. Superoxide detection in a cell-free
system was performed by adding 1uM HerGa or S2Ga, HerPBK10 (at equivalent protein
concentration to HerGa), or PBS directly to assay medium at 100 uL final volume in
separate wells of a 96-well plate, and wells processed as described earlier to measure
superoxide.
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Immunofluorescence
Cells were treated with HerGa or individual components as indicated, then processed for
immunofluorescent histochemical staining following our previously established
procedures 26. Where indicated, fixed cells were incubated for 1h with antibodies against
actin (to assess microfilaments), or tubulin (to assess microtubules). Samples were imaged
by laser scanning fluorescence confocal microscopy as described earlier 3.
Taxol treatment
MDA-MB-435 cells plated in Delta T chambers (104/chamber) received the following
treatments at 36 hours after plating: media was replaced with 0.5 mL media containing
HerGa (1 uM), the equivalent volume of PBS (Mock), or HerGa + 5 uM taxol (after a 15
min taxol pre-treatment, as previously described)26. All treatments included 0.25% DMSO.
The chambers were rocked for 4 hours at 37° C, 5% CO2, followed by supplementation with
an additional 0.5 mL of media and a further 20h incubation. Separate experimental
treatments were independently assessed for TMRM uptake and superoxide levels as
described earlier.
RESULTS
HerPBK10 is required for corrole internalization and cytotoxicity
Evaluation of cellular uptake was performed by confocal fluorescence microscopy of live
HER2+ MDA-MB-435 cells and examination of intracellular corrole fluorescence over time.
The results show that HerGa (1 uM) undergoes internalization within minutes, whereas free
untargeted corrole (S2Ga) at equivalent concentration (1 uM) displays no detectable
accumulation microscopically (Fig. 1A) and by measurement of intracellular fluorescence
intensity (Fig. 1C). Even at 1 hour after initial administration to cells, intracellular S2Ga
fluorescence was not detectable, whereas it was very pronounced for HerGa treated cells
(Fig. 1B). A direct relationship between these findings and cytotoxicity was elucidated from
in vitro dosed toxicity analyses performed 24 h after incubation, showing that cell death
plateaus at concentrations at and above 10 nM HerGa, with a CD50 of ~0.5 nM (Fig. 1D).
This contrasts with the same analysis of S2Ga, which is not toxic up to 100 uM over the
same time frame (Fig. 1D).
Cytosolic HerGa compromises mitochondrial membrane potential
Based on the previous findings, we examined whether HerGa directly impacts mitochondria
by using a Nernstian dye, tetramethyl rhodamine methyl ester (TMRM), to investigate the
ΔΨ (m) of HerGa-treated MDA-MB-435 cells. In contrast to mock treatment, HerGa
significantly reduced the ratio of mitochondrial to cytosolic intensity by 24 hours after
treatment, while HerPBK10 or S2Ga alone had little effect (Fig. 2, D–E). The onset of ΔΨ
(m) collapse could be detected as soon as 1h after HerGa treatment (Fig. 2E), suggesting a
fairly early mitochondrial impact after uptake.
To determine whether endosomal escape is required to facilitate ΔΨ (m) disruption, we
compared HerGa to similar complexes (designated HerGa-2 and HerGa-3) made with carrier
protein (HerK10 and Her, respectively) lacking the endosomal-disrupting penton base
domain (Fig. 3A) 23. In contrast to the reduced TMRM uptake in HerGa-treated cells,
HerGa-2 and HerGa-3 at equivalent corrole dose (1 uM) had negligible effect (Fig. 3B and
C; P<0.05 compared to HerGa), despite the ability of HerGa-2 and HerGa-3 to internalize
into target cells (Fig. 3B, lower panels). HerGa-2 and HerGa-3 also were not cytotoxic to
treated cells, in contrast to the significant reduction in cell survival induced by parental
HerGa (Fig. 3D; P<0.05 compared to HerGa), altogether indicating that ΔΨ (m) disruption
requires direct exposure to HerGa, and leads to cell death.
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HerGa avoids a highly acidic microenvironment after cell entry
Our recent studies indicate that corrole fluorescence lifetime is altered during cell uptake 27,
and specifically shortens in direct relation to microenvironmental pH when tested under
controlled pH conditions (Fig. 4A). We took advantage of this property to determine the
timing of endosome escape. During cellular uptake of HerGa, the corrole fluorescence
lifetime exhibited a time-dependent decrease (Fig. 4B) that correlated with a transition from
a neutral to mildly acidic (pH ~6.5) microenvironment within the first 15 min of uptake (Fig.
4A), but did not decrease below ~700 ps, thus avoiding a highly acidic (pH <6.5)
compartment (Fig. 4B). To confirm whether this is indicative of early endosomal escape, we
used two-photon fluorescence live cell imaging to monitor fluorescence yield and transit of
HerGa during uptake. Intracellular depth analysis shows that HerGa is localized closer to the
cell periphery (shown as two fluorescence peaks at 4 and 10 um depths) early (5 min) after
uptake correlating with an increase in fluorescence intensity, indicative of sequestration into
membrane-juxtaposed vesicles (Fig. 4C). Later time points show HerGa transiting deeper
within the cell, away from the plasma membrane (indicated by a single peak at ~7 um by 1h)
(Fig. 4C), concomitant with a reduction in fluorescence yield that is indicative of diffusion
from vesicles. Taken together with the earlier findings using the endosomolytic-deficient
mutants, these results provide comprehensive evidence that HerGa escapes relatively early
from endosomal vesicles, thus avoiding entry into highly acidic compartments.
Low pH does not induce corrole release from the carrier
We performed a cell-free assay to determine whether S2Ga separates from HerPBK10 in
different pH buffers adjusted to mimic a neutral/extracellular environment (7.5–7.0), mildly
acidic environment such as that in the early endosome or tumor microenvironment (6.5–6.0),
and moderately acidic environment such as that in late endosomes/lysosomes (5.5–5.0). Our
results show that a pH decrease, even to values as low as 5.0, did not yield detectable corrole
release from the carrier protein (Fig. 4D). Taken together with the previous endosomolytic
and pH analyses, these findings suggest that the acidic endosomal microenvironment is
insufficient to induce corrole release from the HerPBK10 carrier protein during uptake.
Cytosolic HerGa elevates intracellular superoxide
We assessed the contribution of reactive oxygen species (ROS) in the cell death mechanism
of HerGa by using a luminol substrate to detect superoxide (O2−) in MDA-MB-435 cells
after exposure to HerGa (1 uM) or individual components (HerPBK10 and S2Ga alone) for
1 hour. While HerPBK10 and S2Ga alone had minor to negligible effect on luminescence
over mock (PBS) treatment, and all three compounds induced low levels of luminescence
over untreated (Control) cells, HerGa induced the highest levels (3–5x the elevation of mock
treatment) (Fig. 5A), suggesting that considerable O2− is generated by HerGa treatment. To
assess whether O2− generation is due to any innate catalytic activity, we repeated this assay
in cell-free conditions. Our results showed that none of the reagents used here produced
detectable luminescence under these conditions (Fig. 5B), indicating that O2− generation
occurs as a cellular response to HerGa treatment. To evaluate the contribution of
endosomolysis on O2− generation, we measured luminescence from cells after treatment
with the endosomolytic-defective complexes, HerGa-2 and HerGa-3. Both HerGa-2 and
HerGa-3 exhibited considerably lower luminescence compared to HerGa, with HerGa-3
yielding no detectable luminescence over mock treatment, indicating that endosomal escape
is necessary for HerGa-mediated O2− generation. To assess the contribution of O2−
generation to mitochondrial damage, we evaluated HerGa-mediated ΔΨ (m) changes in
presence of the superoxide scavenger, Tiron, which sufficiently reduces and prevents O2−
generation at 1–5 mM (Fig. 5C), in agreement with established studies 28. Here, Tiron
restored normal ΔΨ (m) in HerGa-treated cells in comparison to HerGa-treatment without
Tiron (Fig. 5D), indicating that HerGa-induced O2− contributes to ΔΨ (m) disruption.
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HerGa-mediated cytoskeletal disruption occurs downstream of superoxide elevation
We examined the cytoskeletal effect of HerGa uptake by immunofluorescence analysis of
treated MDA-MB-435 cells, and observed that, in comparison to the normal broad cytosolic
distribution of actin filaments and microtubules as seen in mock and control (S2Ga and
HerPBK10 alone) –treated cells, HerGa (1 uM) induced considerable cytoskeletal collapse
by 24h after uptake (Fig. 6). To distinguish whether cytoskeletal disruption resulted as a
direct impact from HerGa or as a downstream event of cell damage, we used the
microtubule stabilizer, taxol, to assess whether preventing microtubule breakdown would
affect ΔΨ (m) disruption and O2− elevation. Taxol significantly reduced HerGa-induced ΔΨ
(m) breakdown (P<0.0001 compared to HerGa)(Fig. 7A) and O2− generation (Fig. 7B),
suggesting that cytoskeletal disruption leads to ROS and mitochondrial damage. However,
the oxygen scavenger, Tiron, prevented HerGa-mediated cytoskeletal breakdown (Fig. 8),
thus suggesting that HerGa causes ROS-mediated cytoskeletal damage. To reconcile which
events are causative, we examined the stage of HerGa uptake (detected by intracellular
corrole fluorescence) affected by taxol treatment. Our findings show that taxol reduces
intracellular accumulation by nearly 70%, (Fig. 7, C–D) indicating that microtubule
stabilization prevents uptake/intracellular transit of HerGa, which in turn prevents the
downstream events of ROS generation, and ROS-mediated damage to mitochondria and the
cytoskeleton. These findings also indicate that dynamic microtubules are required for
mediating HerGa uptake.
DISCUSSION
Our previous studies have established that HerGa binds target HER2+ cells in vitro
specifically through HER ligation, as confirmed through competitive inhibition by free
ligand, and undergoes receptor-mediated endocytosis in response to receptor binding 12.
These same studies also showed that HerPBK10 enabled corrole toxicity at low
(submicromolar) doses in contrast to the free corrole (not attached to HerPBK10), which
required daily doses as high as 35 uM for 3 days to induce appreciable cytotoxicity. These
previous studies suggest that the relatively low dose required for HerGa therapeutic efficacy
is due to the known internalization and membrane-penetration attributes of HerPBK10 that
also enable gene delivery elsewhere 23, while the inability of the free corrole to penetrate the
cell membrane prevents effective toxic impact on target cells, even if it can undergo
endocytosis through attachment to or co-uptake with serum proteins 12. In support of that
hypothesis, we show here that HerGa undergoes internalization, as seen by the accumulation
of intracellular corrole fluorescence over time, whereas free, untargeted corrole (S2Ga) at
equivalent concentration (1 uM) showed no detectable accumulation microscopically.
Correspondingly, HerGa elicited cytotoxicity whereas S2Ga did not, altogether indicating
that HerPBK10 is needed for corrole internalization and mediating corrole toxicity,
especially at low and pharmacologically relevant doses.
One unexpected discovery while conducting these studies has been the direct relationship
between HerGa fluorescence lifetime and pH. This unique property has been useful here for
reporting the intracellular environmental conditions during uptake and could possibly be
exploited in future studies for diagnostic monitoring of the microenvironment in vivo.
Together with two-photon imaging and intracellular depth analysis, the fluorescence lifetime
changes of HerGa during cell uptake indicate that HerG accumulates into membrane-
juxtaposed vesicles of slightly acidic pH, followed by transit away from the plasma
membrane and deeper within the cell that corresponds to escape from endosomal vesicles.
Cytosolic exposure would enable HerGa to transit along cytoskeletal pathways connecting
the plasma membrane to organelles, including the mitochondria. In agreement, the taxol-
mediated reduction of intracellular HerGa indicates that dynamic microtubules are required
for initial transit into the cell and throughout the cytoplasm. The prevention of ΔΨ (m)
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disruption and O2− elevation by taxol also indicates that the cytoskeletal network is
necessary for transport of HerGa to the proximity of oxygen sources, such as the
mitochondria. The prevention of cytoskeletal collapse by Tiron indicates that HerGa-
mediated actin and tubulin disruption lies downstream of O2− elevation. These findings
altogether suggest that the cytoskeletal network is necessary to provide the initial means of
HerGa transport in the cell to oxygen-generating sources (such as the mitochondria) where
HerGa-mediated O2− elevation takes place, and as a result, ultimately becomes a target of
oxidative damage.
Another unexpected finding was that a pH as low as 5.0 does not induce corrole release from
the HerGa complex, thus suggesting that the environment encountered through receptor-
mediated endocytosis and endocytic maturation does not affect complex integrity. Either the
corrole stays bound to the carrier throughout cell entry or is released through a pH-
independent process. Whereas a microscopic analysis of corrole release from HerGa in cells
could verify these findings, the processing required for immunofluorescence assay has
produced fixation artefacts showing false nuclear accumulation of corrole fluorescence (not
shown), thus confounding appropriate evaluation.
Here we find that HerGa, but not its individual constituents, induce ΔΨ (m) collapse that is
mediated through the elevation of superoxide. Moreover, we find through the use of
endosomolytic-deficient mutants that direct exposure of HerGa to the cytosol is necessary
for these events to occur. Taken altogether, these studies have identified the following
stepwise pathway mediating the cytotoxic mechanism of HerGa: HerPBK10 is required to
mediate uptake (Fig. S1, step a) and early endosomal release (Fig. S1, step b), thus enabling
HerGa to avoid low pH compartments such as the late endosome and lysosome after cell
entry. Cytosolic entry is necessary to facilitate downstream O2− elevation (Fig. S1, step c),
which in turn mediates both cytoskeletal and ΔΨ (m) disruption (Fig. S1, steps d and e). As
superoxide generation would cause oxidative damage to cellular processes and structures,
and ΔΨ (m) loss would disrupt cellular metabolic activity, these specific phenomena explain
how HerGa mediates death to target cells.
How HerGa directly interacts with the mitochondrion to elicit these cell-death mediators
remains to be elucidated. Consistent with observations in our previous studies 3, 12, corrole
fluorescence is observable throughout the cytoplasm after HerGa uptake and is not
necessarily specifically targeted to mitochondria. Given the structural similarity of corroles
to porphyrins, HerGa may indirectly affect mitochondrial ROS levels by activating the
mitochondrial benzodiazapine receptor, for which several porphyrins are endogenous
ligands 29. On the other hand, HerGa could impact extra-mitochondrial sources of
superoxide generation, including NADPH oxidase on the plasma membrane and cytoplasmic
enzymes such as xanthine oxidase and nitric oxide synthase 30, which could lead to
mitochondrial damage as well as other downstream apoptotic-like events. Our cell-free
studies show that the corrole itself cannot directly catalyze ROS generation, hence
interactions with host factors are required.
Whereas ROS can activate the intrinsic apoptotic pathway 31, our initial investigations on
the contribution of apoptosis have yielded atypical findings. Mitochondrial permeabilization
typically releases cytochrome c, which activates the caspase cascade resulting in cell death.
Here, moderate but significant elevation in DNA fragmentation, an indicator of apoptotic
cell death, was observed in HerGa but not control –treated cells (Fig. S2, A). However, other
‘classical’ markers of apoptosis were lacking, including phosphatidylserine (PS)
externalization (Fig. S2, A), and elevation of activated caspase 9 and 3 (Fig. S2, B).
Moreover, cytochrome c release was not detected unless the cells were exposed to HerGa at
a 10-fold higher dose over the therapeutic range (Fig. S2, C). Alternative cell death
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pathways may account for these anomalies. For example, caspase-independent
fragmentation of DNA in the absence of PS exposure has been observed in HER2+ T-47D
tumor cells undergoing autophagy 32. Elsewhere, selective release of Smac/DIABLO and
Omi/HtrA2, but not cytochrome c, from mitochondria can result from S100A8/A9-induced
death in tumor cells 33. Mitochondrial release of Smac/DIABLO has been observed in cells
undergoing anchorage-dependent cell death, or anoikis 34, and can function independently of
cytochrome c 35. Importantly, Schafer et al 36 demonstrated that antioxidants inhibit anoikis
in breast cancer cells, suggesting that elevated ROS are required in detachment-mediated
cell death. These examples indicate that further studies are warranted for determining the
contribution of non-classical cell death pathways to HerGa-mediated toxicity, and are
currently ongoing.
Given our recent successful demonstration that targeted corroles eliminate tumor growth 3,
the investigations presented here shed light on the mechanism of corrole-mediated cell
death. These studies will direct our future efforts in engineering modifications into the
corrole and carrier protein that may enable even greater potency and specificity for tumor
cells, thus yielding a therapeutic with optimized efficacy and safety.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. HerPBK10 is required for enhanced internalization & cell death
A, MDA-MB-435 cells were exposed to either HerGa or S2Ga (1 uM final corrole
concentration) and imaged live by fluorescence confocal microscopy. Micrographs show
fluorescence and brightfield overlays at key time points of uptake. B shows a comparison of
fluorescence images acquired at 1h after HerGa or S2Ga uptake. C, Quantification of uptake
in A. The cytosolic accumulation of fluorescence in each cell was quantified by selecting
cytosolic regions and averaging fluorescence intensity using Image J. D, Cell death dose
curve. MDA-MB-435 cells were incubated with HerGa or S2Ga at the indicated doses for
24h before cell survival was assayed by crystal violet (CV) stain. Cell survival is expressed
as CV absorbance of each HerGa-treated sample normalized by mock (PBS) treated
samples, or CV abs of experimental/control. Error bars represent 1 SD of triplicate
treatments.
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Fig. 2. HerGa impacts mitochondrial membrane permeability
MDA-MB-435 cells exposed to HerGa or S2Ga (at 1 uM corrole concentration), HerPBK10,
or PBS received 20nM TMRM in PBS at 24h after treatment, followed by two-photon
excited confocal fluorescence imaging after TMRM uptake. A, Cells displaying respective
fluorescences as the z-stacked maximum intensity projection of each acquired fluorescence
image. B (upper), Mitochondria/cytoplasm ratio of TMRM fluorescence averaged from
three independent experiments represented by A (TMRM uptake). For each experiment, the
average fluorescence intensity for 10 different mitochondria regions and one mitochondria-
free region (cytoplasm) within the same cells were measured respectively. B (lower),
Timecourse of membrane collapse. TMRM uptake during HerGa treatment was assessed as
described in the Methods with mitochondrial/cytoplasm TMRM fluorescence ratios obtained
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at the indicated timepoints after HerGa treatment. *, P<0.05 compared to (B, upper) mock
(PBS) treatment, or (B, lower) time point 0, as determined by 2-tailed unpaired t-test.
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Fig. 3. ΔΨ(m) disruption requires endosome escape
A, Linear protein domain map comparing HerPBK10 and endosomolytic-deficient
derivatives. Each protein is shown from carboxy (left) to amino (right) –terminus,
respectively. Complexes made from combining S2Ga with truncated proteins, HerK10 and
Her, are designated HerGa-2 and HerGa-3, and are compared to parental HerGa for the
effect of each on mitochondrial uptake of TMRM and cell survival. B, TMRM and complex
uptake in MDA-MB-435 cells. Cells were treated with 1 uM (final corrole dose) of each
complex for 24 hours before media exchange and imaging. Where indicated, the media was
replaced with 20nM TMRM in PBS and imaged after mitochondrial TMRM accumulation
reached equilibrium (~1h). Both TMRM and corrole uptake images were collected by two-
photon excited confocal fluorescence microscopy. Fluorescence micrographs show z-
stacked maximum intensity projections of acquired images. Fl/BF, Fluorescence-brightfield
overlay. C, Quantification of TMRM uptake in B (see methods). D, Relative cell survival
(determined by crystal violet stain; see Methods) after treatment in B. *, P<0.05 compared
to HerGa (two-tailed unpaired t-test).
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Fig. 4. Effect of pH on corrole retention and fluorescence lifetime
A, Measurement of HerGa fluorescence lifetime in titrating pH buffers. Fluorescence
lifetime of 25uM HerGa solutions in different pH (5.0, 5.5, 6.0, 6.5, 7.0, and 7.5) was
measured at room temperature and 37°C respectively, in a cell-free system. During the
measurements, the temperature was strictly (~0.1°C) controlled by a ΔT culture dish system.
Before adding the corroles to the chamber, the pH of each corrole solution was confirmed
with a pH meter. B, Monitoring fluorescence lifetime changes of HerGa during uptake into
MDA-MB-435 cells. Fluorescence lifetime images of HerGa were acquired at different time
points (5, 10, 20, 30, 50, 70, and 90min) after addition of 25 uM HerGa into the delta T
chamber containing attached MDA-MB-435 cells. A total of 25 images were acquired (0–
4800ps; Time step: 200ps; gate width: 600ps, Ex: 424nm, light pulse width: 100fs). The
images were analyzed (lower graph) using the first order exponential decay fitting method.
C, Monitoring HerGa fluorescence as a reflection of uptake kinetics. Two-photon
fluorescence imaging-enabled acquisition and analysis of HerGa (25 uM) at various depths
during uptake in MDA-MB-435 cells. Images were acquired at different time points of
HerGa uptake (5, 15, 30, and 60 minutes after addition to cells) and at different z-depths
with a step size of 350nm (Ex: 780nm; Em: 600–650nm). Micrographs show images at 6um
depth at indicated time points during HerGa uptake. The graph shows the fluorescence
intensity z-depth profile of the region selected by a dotted circle in the first micrograph. D,
Evaluating corrole retention under decreasing pH conditions. The acidity of a HEPES-
buffered saline solution was adjusted to the indicated pH levels and pre-assembled HerGa
was added to each pH buffer and incubated for 30 min at room temp (in a cell-free system),
followed by filtration through 10K mwco membranes to remove any released corrole. The
absorbances at 424 nm (maximum absorbance wavelength of gallium corrole) were obtained
from the preassembled complex before incubation with each pH buffer (“Input”) and the
filtered complex recovered from the ultrafiltration device after incubation with each pH
buffer (“Retentate”). Error bars represent SD of repeat experiments. N=2–3 samples/pH per
experiment.
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Fig. 5. Cytosolic HerGa induces superoxide generation
MDA-MB-435 cells treated with 1 uM HerGa, S2Ga, HerPBK10, or PBS (mock) for 1h
were analyzed for superoxide via chemiluminescence detection (see Methods). Graphs (A–
C) displays relative luminescence unit (RLU) decay over time. A, Contribution of
endosomolysis on superoxide generation. MDA-MB-435 cells were treated and assayed for
chemiluminescence as described earlier. HerGa, HerGa-2, HerGa-3, and S2Ga were added
to cells at 1 uM corrole concentration. Individual components were added at the equivalent
protein concentration to each respective complex. B, Lack of superoxide generation in a
cell-free system. HerGa (1 uM) and equivalent concentrations of S2Ga, HerPBK10, or PBS
were added directly to superoxide anion assay medium and luminol oxidation was measured
as described in the Methods. C, Reduction of HerGa-mediated superoxide generation in
MDA-MB-435 cells by the superoxide scavenger, Tiron. Cells were incubated with 1 mM
Tiron for 1h before treatment with 1 uM HerGa for 24h, followed by superoxide
measurement as described earlier. D, Effect of Tiron on HerGa-mediated ΔΨ (m) disruption.
Cells were incubated with the indicated concentrations of Tiron before treatment with 1 uM
HerGa for 24h, followed by measurement of TMRM uptake as described earlier. *, P<0.02
compared to HerGa alone, as determined by two-tailed unpaired t test.
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Fig. 6. HerGa disrupts the cytoskeleton
A, MDA-MB-435 cells treated with S2Ga or HerGa at 1uM final corrole concentration, or
HerPBK10 alone at equivalent protein concentration to HerGa, were assessed for
cytoskeletal changes by 24h of treatment by fluorescence labeling of actin (red) or tubulin
(green). Blue, nucleus. Epi-fluorescence imaging was performed using filter cubes to detect
DAPI (ex: 380nm and em: 400nm), FITC (ex: 488nm and em: 530nm), CY3 (ex: 550nm and
em: 580nm), and corrole (ex: 425nm and em: 620nm), and images collected by a 40x
objective (Nikon Planfluor, NA: 0.75). To increase image contrast, background subtraction
from each acquired image was performed using ImageJ. Bar, ~20 microns.
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Fig. 7. Microtubule stabilization abrogates events downstream of HerGa uptake
MDA-MB-435 cells were incubated in media containing 5 uM taxol for 15 min before
exposure to HerGa (see Methods). At 24h after exposure, cells received (A) 20nM TMRM
and were monitored for mitochondrial TMRM accumulation as described previously; or (B)
luminol and assayed for superoxide levels as described in the Methods. *, P<0.0001
compared to HerGa treatment. **, P<0.0001. Statistical significances determined by two-
tailed unpaired t-tests. C–D, Effect of taxol on HerGa uptake. C, Confocal images were
acquired of live MDA-MB-435 cells after treatment with 5uM HerGa (−/+ pretreatment
with 5 uM taxol; see Methods). D, Cytosolic fluorescence from the same cell region per time
point was measured and average fluorescence variations plotted over time, comparing
HerGa −/+ taxol.
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Fig. 8. HerGa-mediated superoxide generation disrupts the cytoskeleton
Where indicated, MDA-MB-435 cells were incubated with the indicated concentrations of
Tiron for 1h before treatment with 1 uM HerGa or Mock (PBS) treatment for 24h, followed
by fixation and immunofluorescence processing to label actin (red), tubulin (green), and
nuclei (blue). Cells were imaged as described in Fig. 6. Bar, ~20 microns.
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